Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

NCT01520870 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Brain Tumor, Recurrent

Interventions

DRUG: PF-299804 (Dacomitinib)

Sponsor

Grupo Español de Investigación en Neurooncología

Collaborators

[object Object]